158 related articles for article (PubMed ID: 37894394)
1. A Prognostic Model to Predict Ruxolitinib Discontinuation and Death in Patients with Myelofibrosis.
Palandri F; Palumbo GA; Bonifacio M; Elli EM; Tiribelli M; Auteri G; Trawinska MM; Polverelli N; Benevolo G; Tieghi A; Cavalca F; Caocci G; Beggiato E; Binotto G; Cavazzini F; Miglino M; Bosi C; Crugnola M; Bocchia M; Martino B; Pugliese N; Venturi M; Isidori A; Cattaneo D; Krampera M; Pane F; Cilloni D; Semenzato G; Lemoli RM; Cuneo A; Abruzzese E; Branzanti F; Vianelli N; Cavo M; Heidel F; Iurlo A; Breccia M
Cancers (Basel); 2023 Oct; 15(20):. PubMed ID: 37894394
[TBL] [Abstract][Full Text] [Related]
2. Ruxolitinib in cytopenic myelofibrosis: Response, toxicity, drug discontinuation, and outcome.
Palandri F; Breccia M; Mazzoni C; Auteri G; Elli EM; Trawinska MM; Polverelli N; Tiribelli M; Benevolo G; Iurlo A; Tieghi A; Heidel FH; Caocci G; Beggiato E; Binotto G; Cavazzini F; Miglino M; Bosi C; Crugnola M; Bocchia M; Martino B; Pugliese N; Biondo M; Venturi M; Scaffidi L; Isidori A; Cattaneo D; Krampera M; Pane F; Cilloni D; Semenzato G; Lemoli RM; Cuneo A; Abruzzese E; Bartoletti D; Paglia S; Vianelli N; Cavo M; Bonifacio M; Palumbo GA
Cancer; 2023 Jun; 129(11):1704-1713. PubMed ID: 36932983
[TBL] [Abstract][Full Text] [Related]
3. Light and shade of ruxolitinib: positive role of early treatment with ruxolitinib and ruxolitinib withdrawal syndrome in patients with myelofibrosis.
Baek DW; Cho HJ; Lee JM; Kim J; Moon JH; Sohn SK
Expert Rev Hematol; 2022 Jul; 15(7):573-581. PubMed ID: 35679520
[TBL] [Abstract][Full Text] [Related]
4. Life after ruxolitinib: Reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosis.
Palandri F; Breccia M; Bonifacio M; Polverelli N; Elli EM; Benevolo G; Tiribelli M; Abruzzese E; Iurlo A; Heidel FH; Bergamaschi M; Tieghi A; Crugnola M; Cavazzini F; Binotto G; Isidori A; Sgherza N; Bosi C; Martino B; Latagliata R; Auteri G; Scaffidi L; Griguolo D; Trawinska M; Cattaneo D; Catani L; Krampera M; Lemoli RM; Cuneo A; Semenzato G; Foà R; Di Raimondo F; Bartoletti D; Cavo M; Palumbo GA; Vianelli N
Cancer; 2020 Mar; 126(6):1243-1252. PubMed ID: 31860137
[TBL] [Abstract][Full Text] [Related]
5. Ruxolitinib rechallenge in resistant or intolerant patients with myelofibrosis: Frequency, therapeutic effects, and impact on outcome.
Palandri F; Tiribelli M; Breccia M; Bartoletti D; Elli EM; Benevolo G; Martino B; Cavazzini F; Tieghi A; Iurlo A; Abruzzese E; Pugliese N; Binotto G; Caocci G; Auteri G; Cattaneo D; Trawinska MM; Stella R; Scaffidi L; Polverelli N; Micucci G; Masselli E; Crugnola M; Bosi C; Heidel FH; Latagliata R; Pane F; Cuneo A; Krampera M; Semenzato G; Lemoli RM; Cavo M; Vianelli N; Bonifacio M; Palumbo GA
Cancer; 2021 Aug; 127(15):2657-2665. PubMed ID: 33794557
[TBL] [Abstract][Full Text] [Related]
6. Differences in presenting features, outcome and prognostic models in patients with primary myelofibrosis and post-polycythemia vera and/or post-essential thrombocythemia myelofibrosis treated with ruxolitinib. New perspective of the MYSEC-PM in a large multicenter study
Palandri F; Palumbo GA; Iurlo A; Polverelli N; Benevolo G; Breccia M; Abruzzese E; Tiribelli M; Bonifacio M; Tieghi A; Isidori A; Martino B; Sgherza N; D'Adda M; Bergamaschi M; Crugnola M; Cavazzini F; Bosi C; Binotto G; Auteri G; Latagliata R; Ibatici A; Scaffidi L; Penna D; Cattaneo D; Soci F; Trawinska M; Russo D; Cuneo A; Semenzato G; Di Raimondo F; Aversa F; Lemoli RM; Heidel F; Reggiani MLB; Bartoletti D; Cavo M; Catani L; Vianelli N
Semin Hematol; 2018 Oct; 55(4):248-255. PubMed ID: 30502854
[TBL] [Abstract][Full Text] [Related]
7. Incidence of blast phase in myelofibrosis patients according to anemia severity at ruxolitinib start and during therapy.
Palandri F; Palumbo GA; Benevolo G; Iurlo A; Elli EM; Abruzzese E; Polverelli N; Tiribelli M; Auteri G; Tieghi A; Caocci G; Binotto G; Cavazzini F; Branzanti F; Beggiato E; Miglino M; Bosi C; Crugnola M; Bocchia M; Martino B; Pugliese N; Scaffidi L; Venturi M; Duminuco A; Isidori A; Cattaneo D; Krampera M; Pane F; Cilloni D; Semenzato G; Lemoli RM; Cuneo A; Trawinska MM; Vianelli N; Cavo M; Bonifacio M; Breccia M
Cancer; 2024 Apr; 130(8):1270-1280. PubMed ID: 38153814
[TBL] [Abstract][Full Text] [Related]
8. A prognostic model to predict survival after 6 months of ruxolitinib in patients with myelofibrosis.
Maffioli M; Mora B; Ball S; Iurlo A; Elli EM; Finazzi MC; Polverelli N; Rumi E; Caramella M; Carraro MC; D'Adda M; Molteni A; Sissa C; Lunghi F; Vismara A; Ubezio M; Guidetti A; Caberlon S; Anghilieri M; Komrokji R; Cattaneo D; Della Porta MG; Giorgino T; Bertù L; Brociner M; Kuykendall A; Passamonti F
Blood Adv; 2022 Mar; 6(6):1855-1864. PubMed ID: 35130339
[TBL] [Abstract][Full Text] [Related]
9. Between a rux and a hard place: evaluating salvage treatment and outcomes in myelofibrosis after ruxolitinib discontinuation.
Kuykendall AT; Shah S; Talati C; Al Ali N; Sweet K; Padron E; Sallman DA; Lancet JE; List AF; Zuckerman KS; Komrokji RS
Ann Hematol; 2018 Mar; 97(3):435-441. PubMed ID: 29189896
[TBL] [Abstract][Full Text] [Related]
10. Peripheral blasts are associated with responses to ruxolitinib and outcomes in patients with chronic-phase myelofibrosis.
Palandri F; Bartoletti D; Iurlo A; Bonifacio M; Abruzzese E; Caocci G; Elli EM; Auteri G; Tiribelli M; Polverelli N; Miglino M; Heidel FH; Tieghi A; Benevolo G; Beggiato E; Fava C; Cavazzini F; Pugliese N; Binotto G; Bosi C; Martino B; Crugnola M; Ottaviani E; Micucci G; Trawinska MM; Cuneo A; Bocchia M; Krampera M; Pane F; Lemoli RM; Cilloni D; Vianelli N; Cavo M; Palumbo GA; Breccia M
Cancer; 2022 Jul; 128(13):2449-2454. PubMed ID: 35363892
[TBL] [Abstract][Full Text] [Related]
11. Risk factors for progression to blast phase and outcome in 589 patients with myelofibrosis treated with ruxolitinib: Real-world data.
Palandri F; Breccia M; Tiribelli M; Bonifacio M; Benevolo G; Iurlo A; Elli EM; Binotto G; Tieghi A; Polverelli N; Martino B; Abruzzese E; Bergamaschi M; Heidel FH; Cavazzini F; Crugnola M; Bosi C; Isidori A; Auteri G; Forte D; Latagliata R; Griguolo D; Cattaneo D; Trawinska M; Bartoletti D; Krampera M; Semenzato G; Lemoli RM; Cuneo A; Di Raimondo F; Vianelli N; Cavo M; Palumbo GA
Hematol Oncol; 2020 Aug; 38(3):372-380. PubMed ID: 32271957
[TBL] [Abstract][Full Text] [Related]
12. AIPSS-MF machine learning prognostic score validation in a cohort of myelofibrosis patients treated with ruxolitinib.
Duminuco A; Mosquera-Orgueira A; Nardo A; Di Raimondo F; Palumbo GA
Cancer Rep (Hoboken); 2023 Oct; 6(10):e1881. PubMed ID: 37553891
[TBL] [Abstract][Full Text] [Related]
13. Long-term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls.
Verstovsek S; Kantarjian HM; Estrov Z; Cortes JE; Thomas DA; Kadia T; Pierce S; Jabbour E; Borthakur G; Rumi E; Pungolino E; Morra E; Caramazza D; Cazzola M; Passamonti F
Blood; 2012 Aug; 120(6):1202-9. PubMed ID: 22718840
[TBL] [Abstract][Full Text] [Related]
14. Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study.
Harrison CN; Schaap N; Vannucchi AM; Kiladjian JJ; Tiu RV; Zachee P; Jourdan E; Winton E; Silver RT; Schouten HC; Passamonti F; Zweegman S; Talpaz M; Lager J; Shun Z; Mesa RA
Lancet Haematol; 2017 Jul; 4(7):e317-e324. PubMed ID: 28602585
[TBL] [Abstract][Full Text] [Related]
15. Relevant Clinical Factors in Patients with Myelofibrosis on Ruxolitinib for 5 or More Years.
Masarova L; Bose P; Pemmaraju N; Zhou L; Pierce S; Estrov Z; Kantarjian H; Verstovsek S
Acta Haematol; 2023; 146(6):522-529. PubMed ID: 37699357
[TBL] [Abstract][Full Text] [Related]
16. Interim analysis of safety and efficacy of ruxolitinib in patients with myelofibrosis and low platelet counts.
Talpaz M; Paquette R; Afrin L; Hamburg SI; Prchal JT; Jamieson K; Terebelo HR; Ortega GL; Lyons RM; Tiu RV; Winton EF; Natrajan K; Odenike O; Claxton D; Peng W; O'Neill P; Erickson-Viitanen S; Leopold L; Sandor V; Levy RS; Kantarjian HM; Verstovsek S
J Hematol Oncol; 2013 Oct; 6(1):81. PubMed ID: 24283202
[TBL] [Abstract][Full Text] [Related]
17. Baseline factors associated with response to ruxolitinib: an independent study on 408 patients with myelofibrosis.
Palandri F; Palumbo GA; Bonifacio M; Tiribelli M; Benevolo G; Martino B; Abruzzese E; D'Adda M; Polverelli N; Bergamaschi M; Tieghi A; Cavazzini F; Ibatici A; Crugnola M; Bosi C; Latagliata R; Di Veroli A; Scaffidi L; de Marchi F; Cerqui E; Anaclerico B; De Matteis G; Spinsanti M; Sabattini E; Catani L; Aversa F; Di Raimondo F; Vitolo U; Lemoli RM; Fanin R; Merli F; Russo D; Cuneo A; Bacchi Reggiani ML; Cavo M; Vianelli N; Breccia M
Oncotarget; 2017 Oct; 8(45):79073-79086. PubMed ID: 29108288
[TBL] [Abstract][Full Text] [Related]
18. Trends in overall mortality among US veterans with primary myelofibrosis.
Tashi T; Yu J; Pandya S; Dieyi C; Scherber R; Parasuraman S
BMC Cancer; 2023 Jan; 23(1):48. PubMed ID: 36641455
[TBL] [Abstract][Full Text] [Related]
19. Long-term survival in patients treated with ruxolitinib for myelofibrosis: COMFORT-I and -II pooled analyses.
Verstovsek S; Gotlib J; Mesa RA; Vannucchi AM; Kiladjian JJ; Cervantes F; Harrison CN; Paquette R; Sun W; Naim A; Langmuir P; Dong T; Gopalakrishna P; Gupta V
J Hematol Oncol; 2017 Sep; 10(1):156. PubMed ID: 28962635
[TBL] [Abstract][Full Text] [Related]
20. Management of cytopenias in patients with myelofibrosis treated with ruxolitinib and effect of dose modifications on efficacy outcomes.
Verstovsek S; Gotlib J; Gupta V; Atallah E; Mascarenhas J; Quintas-Cardama A; Sun W; Sarlis NJ; Sandor V; Levy RS; Kantarjian HM; Mesa RA
Onco Targets Ther; 2013; 7():13-21. PubMed ID: 24368888
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
